Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Takeshi Gocho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8463-905X; OpenAlex author ID A5075524860. Sources: OpenAlex.

Their work

Papers
27 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 27

  1. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  2. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  3. Sialic Acid-Fibronectin-negative and CD-44-positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition. Co-author DOI 10.21873/anticanres.17965↗
  4. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. First author DOI 10.21873/cdp.10600↗
  5. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  6. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  7. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  8. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  9. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  10. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  11. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  12. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. First author DOI 10.21873/anticanres.16150↗
  13. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  14. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  15. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  16. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  17. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12447↗
  18. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Co-author DOI 10.1007/s00423-021-02166-0↗
  19. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  20. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001767↗
  21. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.21873/anticanres.12485↗
  22. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  23. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour sit… Co-author DOI 10.3109/00365521.2015.1121515↗
  24. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. First author DOI 10.1158/1535-7163.mct-14-0420↗
  25. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.019↗
  26. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e31823a53b2↗
  27. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Co-author PMID 23155291↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 19 shared papers, 2021–2026 · strength 3.78
  2. Yoshihiro Shirai · 19 shared papers, 2018–2026 · strength 3.55
  3. Kenei Furukawa · 19 shared papers, 2012–2026 · strength 3.26
  4. Koichiro Haruki · 18 shared papers, 2012–2026 · strength 2.93
  5. Shinji Onda · 16 shared papers, 2018–2026 · strength 2.89
  6. Masashi Tsunematsu · 12 shared papers, 2022–2026 · strength 2.58
  7. Ryoga Hamura · 13 shared papers, 2018–2026 · strength 2.14
  8. Michinori Matsumoto · 9 shared papers, 2023–2026 · strength 2.10
  9. Taro Sakamoto · 9 shared papers, 2018–2026 · strength 1.63
  10. Tadashi Uwagawa · 9 shared papers, 2018–2026 · strength 1.46
  11. Norimitsu Okui · 5 shared papers, 2024–2026 · strength 1.20
  12. Mitsuru Yanagaki · 5 shared papers, 2021–2026 · strength 1.02
  13. Tadashi Uwagawa · 6 shared papers, 2012–2025 · strength 0.81
  14. Kyohei Abe · 5 shared papers, 2018–2025 · strength 0.79
  15. Shuichi Fujioka · 4 shared papers, 2022–2025 · strength 0.70
  16. Yoshiaki Tanji · 3 shared papers, 2023–2026 · strength 0.69
  17. Hiroaki Shiba · 6 shared papers, 2012–2022 · strength 0.65
  18. Katsuhiko K. Yanaga · 8 shared papers, 2012–2022 · strength 0.60
  19. Hironori Shiozaki · 4 shared papers, 2021–2023 · strength 0.57
  20. Yuta Yamada · 2 shared papers, 2024–2026 · strength 0.47
  21. Tomohiko Taniai · 3 shared papers, 2021–2023 · strength 0.41
  22. Takashi Horiuchi · 3 shared papers, 2018–2021 · strength 0.34
  23. Yuki Fujiwara · 5 shared papers, 2012–2022 · strength 0.33
  24. Takashi Aida · 1 shared paper, 2026 · strength 0.26
  25. Yosuke Igarashi · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.